Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Backers
2
Angelini Ventures, Kurma Partners
Momentum
0/100
no fresh signals
Registers and programsofficial lists and records that name the company
Legal entity deutsch BV its site
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
KiloGen Therapeutics specializes in proximity pharmacology, molecular glues, targeted protein degradation (TPD), biotechnology, drug…
KymeraTx51-200 employees • 25 roles
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
Together we are transforming the future of Targeted Protein Degradation Our people are at the heart of our success Our commitment to…
Epicrispr BiotechnologiesSeries C $90M · 1 mo ago • 201-500 employees
Home. Developing therapies to dynamically control gene expression and treat complex disease.
Vico TherapeuticsFounded 2019 • 51-200 employees
Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly…
Evlabio11-50 employees
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody…

Overview

Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that offers new hope for eradicating disease-causing targets through protein degradation.